NCT07133633
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 41 versions: 40 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Trial sites expanded: 105 → 108 locations
- Primary completion moved earlier from Jun 15, 2027 to Mar 29, 2027
- Minor Study sites: 106 to 107
- Minor Site details revised at 3 of 106 sites
- Minor Study sites: 105 to 106
- Notable Eligibility criteria expanded, about 8 words
- Secondary endpoints: details revised at 12 of 14 entries
- Site details revised at 22 of 105 sites
Show 11 earlier versionsHide 11 earlier versions
- Minor Site details revised at 1 of 105 sitesv36
- Minor Study sites: 104 to 105v35
- Minor Site details revised at 3 of 104 sitesv34
- Minor Site details revised at 1 of 104 sitesv32
- Minor Site details revised at 1 of 104 sitesv31
- Minor Study sites: 102 to 104v30
- Minor Study sites: 101 to 102v29
- Minor Study sites: 100 to 101v28
- Minor Site details revised at 1 of 100 sitesv27
- Minor Study sites: 99 to 100v26
- Minor Study sites: 98 to 99v25
- Minor Trial sites expanded: 95 → 98 locationsv24
- Minor Trial sites expanded: 89 → 95 locationsv23
- Minor Study sites: 88 to 89v22
- Minor Study sites: 81 to 88v21
- Minor Study sites: 73 to 81v20
- Minor Study sites: 69 to 73v19
- Minor Study sites: 61 to 69v18
- Minor Study sites: 58 to 61v17
- Minor Study sites: 57 to 58v16
- Minor Study sites: 54 to 57v15
- Minor Study sites: 53 to 54v14
- Minor Study sites: 52 to 53v13
- Minor Study sites: 45 to 52v12
- Minor Study sites: 37 to 45v11
- Minor Study sites: 34 to 37v10
- Minor Study sites: 30 to 34v9
- Minor Study sites: 28 to 30v8
- Minor Study sites: 19 to 28v7
- Minor Study sites: 15 to 19v6
- Minor Study sites: 14 to 15v5
- Minor Study sites: 3 to 14v4
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Start date changed from estimate of Sep 18, 2025 to Sep 26, 2025
- Minor Study description expanded, about 27 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (14)
Show 9 moreShow less
Arms and interventions
Participants receive a high dose of tulisokibart.
Participants receive a medium dose of tulisokibart.
Participants receive a low dose of tulisokibart and are rerandomized at week 16 to a medium or high dose of tulisokibart.
Participants receive a matched placebo dose and are rerandomized at week 16 to a medium or high dose of tulisokibart.
Drugs: Tulisokibart, Placebo
Sites
108 sites in 14 countries
United States 38, China 9, Ukraine 9, Germany 7, Taiwan 7, Poland 6, Turkey (Türkiye) 6, Brazil 5, Chile 5, United Kingdom 4, Canada 3, Colombia 3, Netherlands 3, South Korea 3